JP2019534036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534036A5 JP2019534036A5 JP2019532192A JP2019532192A JP2019534036A5 JP 2019534036 A5 JP2019534036 A5 JP 2019534036A5 JP 2019532192 A JP2019532192 A JP 2019532192A JP 2019532192 A JP2019532192 A JP 2019532192A JP 2019534036 A5 JP2019534036 A5 JP 2019534036A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- oncolytic adenovirus
- bite
- oncolytic
- adenovirus according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130173A JP7525558B2 (ja) | 2016-08-29 | 2022-08-17 | 二重特異性ｔ細胞アクチベーターで武装したアデノウイルス |
| JP2024114614A JP2024147722A (ja) | 2016-08-29 | 2024-07-18 | 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1614607.8 | 2016-08-29 | ||
| GBGB1614607.8A GB201614607D0 (en) | 2016-08-29 | 2016-08-29 | Modified adenovirus |
| GBGB1700663.6A GB201700663D0 (en) | 2017-01-13 | 2017-01-13 | Modified adenovirus |
| GB1700663.6 | 2017-01-13 | ||
| GB1706219.1 | 2017-04-19 | ||
| GBGB1706219.1A GB201706219D0 (en) | 2017-04-19 | 2017-04-19 | Modified adenovirus |
| GB1713765.4 | 2017-08-28 | ||
| GBGB1713765.4A GB201713765D0 (en) | 2017-08-28 | 2017-08-28 | Modified adenovirus |
| PCT/EP2017/071674 WO2018041838A1 (en) | 2016-08-29 | 2017-08-29 | Adenovirus armed with bispecific t cell engager (bite) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130173A Division JP7525558B2 (ja) | 2016-08-29 | 2022-08-17 | 二重特異性ｔ細胞アクチベーターで武装したアデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534036A JP2019534036A (ja) | 2019-11-28 |
| JP2019534036A5 true JP2019534036A5 (enExample) | 2020-10-08 |
| JP7212620B2 JP7212620B2 (ja) | 2023-01-25 |
Family
ID=59923381
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532192A Active JP7212620B2 (ja) | 2016-08-29 | 2017-08-29 | 二重特異性ｔ細胞アクチベーターで武装したアデノウイルス |
| JP2019507924A Pending JP2019532621A (ja) | 2016-08-29 | 2017-08-29 | 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス |
| JP2022130173A Active JP7525558B2 (ja) | 2016-08-29 | 2022-08-17 | 二重特異性ｔ細胞アクチベーターで武装したアデノウイルス |
| JP2024114614A Pending JP2024147722A (ja) | 2016-08-29 | 2024-07-18 | 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507924A Pending JP2019532621A (ja) | 2016-08-29 | 2017-08-29 | 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス |
| JP2022130173A Active JP7525558B2 (ja) | 2016-08-29 | 2022-08-17 | 二重特異性ｔ細胞アクチベーターで武装したアデノウイルス |
| JP2024114614A Pending JP2024147722A (ja) | 2016-08-29 | 2024-07-18 | 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US12049513B2 (enExample) |
| EP (3) | EP4273252A3 (enExample) |
| JP (4) | JP7212620B2 (enExample) |
| KR (2) | KR102491752B1 (enExample) |
| CN (4) | CN110214025B (enExample) |
| AU (2) | AU2017320776B2 (enExample) |
| BR (1) | BR112019003866A2 (enExample) |
| CA (2) | CA3033267A1 (enExample) |
| CL (1) | CL2019000510A1 (enExample) |
| CO (1) | CO2019002371A2 (enExample) |
| ES (1) | ES2983916T3 (enExample) |
| IL (2) | IL264902B2 (enExample) |
| MX (2) | MX2019002328A (enExample) |
| MY (1) | MY197324A (enExample) |
| PH (1) | PH12019500436A1 (enExample) |
| SG (2) | SG11201901716TA (enExample) |
| WO (2) | WO2018041838A1 (enExample) |
| ZA (1) | ZA201900644B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| CA3211863A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| SI3021859T1 (en) | 2013-10-25 | 2018-04-30 | Psioxus Therapeutics Limited | Oncolytic adenoviruses equipped with heterologous genes |
| BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
| SG11201704274QA (en) | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
| WO2016086189A2 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| KR102854512B1 (ko) | 2015-04-30 | 2025-09-04 | 아카미스 바이오 리미티드 | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| KR20180108590A (ko) | 2015-12-17 | 2018-10-04 | 싸이오서스 테라퓨틱스 엘티디. | 항-tcr-복합체 항체 또는 단편을 암호화하는 바이러스 |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN110214025B (zh) | 2016-08-29 | 2024-08-02 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| RU2771110C2 (ru) * | 2017-07-26 | 2022-04-26 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
| EP3731850A4 (en) * | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| WO2019195623A2 (en) * | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| EP3781130A4 (en) * | 2018-04-11 | 2022-01-26 | Precision Molecular Inc. | THERAPEUTIC CONSTRUCTS FOR TREATMENT OF CANCER |
| CN112867734A (zh) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| EP3847186A4 (en) * | 2018-09-05 | 2022-05-18 | Memorial Sloan Kettering Cancer Center | Pleural effusion-based methods for assessing immunoresponsive cell activity |
| EP3861016A2 (en) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| CN109709341B (zh) * | 2019-01-17 | 2020-12-15 | 浙江大学 | 骨关节炎第二亚型的生物标记物以及用途 |
| CN113646334B (zh) * | 2019-02-20 | 2025-09-16 | 国家儿童医院研究所 | 癌症靶向的、病毒编码的、可调节的t细胞（catvert）或nk细胞（catvern）接头 |
| AU2020232605A1 (en) | 2019-03-01 | 2021-10-21 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN116322728A (zh) * | 2020-08-14 | 2023-06-23 | 上海行深生物科技有限公司 | 水疱性口炎病毒及其治疗用途 |
| KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| TW202229546A (zh) * | 2020-09-27 | 2022-08-01 | 美商建南德克公司 | 高通量多參數免疫細胞接合物篩選測定 |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| WO2022148736A1 (en) * | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| CN115161293B (zh) * | 2021-04-01 | 2024-11-15 | 南京惟亚德生物医药有限公司 | 一种编码双特异性t细胞衔接子的溶瘤痘苗病毒及其制备方法和应用 |
| US20250163157A1 (en) | 2022-02-27 | 2025-05-22 | Boehringer Ingelheim International Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
| EP4562028A1 (en) | 2022-07-28 | 2025-06-04 | Akamis Bio Limited | Virus encoding transgenes to complement cellular therapy |
| WO2024047114A1 (en) | 2022-08-31 | 2024-03-07 | Universität Zürich | Adenoviral-based in situ delivery of bispecific t cell engagers |
| AU2024277678A1 (en) | 2023-05-25 | 2025-11-27 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| PT667912E (pt) | 1993-07-13 | 2008-10-15 | Centelion | Vectores adenovirais deficientes e utilização em terapia génica |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| US5587299A (en) | 1994-04-20 | 1996-12-24 | Memorial Sloan-Kettering Cancer Center | Isolated nucleic acid molecule coding for fibroblast activation protein alpha and uses thereof |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| ATE374821T1 (de) | 1997-02-20 | 2007-10-15 | Univ Johns Hopkins Med | Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| HUP0003911A3 (en) | 1997-10-09 | 2007-11-28 | Pro Virus | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| AU767975B2 (en) | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
| ATE361988T1 (de) | 1998-12-09 | 2007-06-15 | Us Gov Health & Human Serv | Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden |
| AU774437B2 (en) | 1999-02-22 | 2004-06-24 | Transgene S.A. | Method for obtaining a purified viral preparation |
| HK1045716A1 (zh) | 1999-04-09 | 2002-12-06 | 阿文蒂斯药物股份有限公司 | 用於保存感染性重組腺病毒的組合物 |
| NZ515582A (en) | 1999-05-17 | 2003-11-28 | Crucell Holland B | Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 |
| ATE291633T1 (de) | 1999-06-01 | 2005-04-15 | Univ Washington | Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| BRPI0107736B8 (pt) | 2000-01-21 | 2021-05-25 | Biovex Ltd | cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1 |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| JP2003534806A (ja) | 2000-05-31 | 2003-11-25 | ジェンベク、インコーポレイティッド | アデノウイルスベクターのターゲティングの方法および組成物 |
| JP2004500863A (ja) | 2000-06-06 | 2004-01-15 | ブリストル−マイヤーズ スクイブ カンパニー | 免疫調節に有用なｂ７関連核酸およびポリペプチド |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| EP1348030B1 (en) | 2001-01-04 | 2009-11-25 | Wadell, Göran | Viral vector for gene therapy |
| US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| US20030219410A1 (en) | 2002-02-01 | 2003-11-27 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated to PODs |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| WO2003092594A2 (en) | 2002-04-30 | 2003-11-13 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| WO2004087930A1 (en) | 2003-03-28 | 2004-10-14 | Saint Louis University | Adenovirus replication-competent vectors expressing trail |
| US20050136035A1 (en) | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| CA2527020A1 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EP1646717A4 (en) | 2003-07-18 | 2006-12-20 | Onyx Pharma Inc | ADENOVIRAL VECTORS OF SUB-GROUP B FOR THE TREATMENT OF DISEASES |
| PL1673398T3 (pl) * | 2003-10-16 | 2011-05-31 | Amgen Res Munich Gmbh | Multispecyficzne deimmunizowane cząsteczki wiążące CD3 |
| US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| PT1749098E (pt) | 2004-05-26 | 2011-02-02 | Bayer Schering Pharma Ag | Adenovírus quimérico para utilização no tratamento do cancro |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| JP2008511336A (ja) | 2004-09-01 | 2008-04-17 | アメリカ合衆国 | 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法 |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| CN1961961B (zh) | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| EP2094284A2 (en) | 2006-12-22 | 2009-09-02 | Bayer Schering Pharma AG | Generation of oncolytic adenoviruses and uses thereof |
| CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| WO2009097443A2 (en) | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
| US20110086005A1 (en) | 2008-05-27 | 2011-04-14 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| KR101837053B1 (ko) | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| US8999342B2 (en) | 2009-10-02 | 2015-04-07 | Ludwig Institute For Cancer Research, Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| KR101721725B1 (ko) | 2010-08-16 | 2017-03-31 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 아데노바이러스 조립 방법 |
| EP3321286B1 (en) | 2011-08-23 | 2021-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| US20140316369A1 (en) | 2011-11-14 | 2014-10-23 | Regenerative Sciences, Llc | Suspended particle delivery systems and methods |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| US10633451B2 (en) * | 2012-02-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine |
| SG10201603896RA (en) | 2012-05-04 | 2016-07-28 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| US20160000842A1 (en) * | 2013-03-05 | 2016-01-07 | Baylor College Of Medicine | Oncolytic virus |
| CN105592788A (zh) | 2013-03-06 | 2016-05-18 | 塞罗拉公司 | 用于脑健康的多模态生理评估的形成因素 |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| SI3021859T1 (en) * | 2013-10-25 | 2018-04-30 | Psioxus Therapeutics Limited | Oncolytic adenoviruses equipped with heterologous genes |
| JP2016540505A (ja) | 2013-11-22 | 2016-12-28 | ディーエヌエートリックス インコーポレイテッド | アデノウイルス発現免疫細胞刺激受容体アゴニスト |
| CN106459213B (zh) | 2014-04-03 | 2020-12-01 | Igm生物科学股份有限公司 | 修饰的j链 |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| WO2016030489A2 (en) * | 2014-08-27 | 2016-03-03 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| US11485791B2 (en) * | 2015-03-17 | 2022-11-01 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies |
| KR102854512B1 (ko) | 2015-04-30 | 2025-09-04 | 아카미스 바이오 리미티드 | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
| KR20180108590A (ko) | 2015-12-17 | 2018-10-04 | 싸이오서스 테라퓨틱스 엘티디. | 항-tcr-복합체 항체 또는 단편을 암호화하는 바이러스 |
| WO2017161360A2 (en) | 2016-03-18 | 2017-09-21 | Nant Holdings Ip, Llc | Multimodal vector for dendritic cell infection |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN110214025B (zh) | 2016-08-29 | 2024-08-02 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
-
2017
- 2017-08-29 CN CN201780057768.4A patent/CN110214025B/zh active Active
- 2017-08-29 CA CA3033267A patent/CA3033267A1/en not_active Abandoned
- 2017-08-29 KR KR1020227026101A patent/KR102491752B1/ko active Active
- 2017-08-29 JP JP2019532192A patent/JP7212620B2/ja active Active
- 2017-08-29 IL IL264902A patent/IL264902B2/en unknown
- 2017-08-29 US US16/329,098 patent/US12049513B2/en active Active
- 2017-08-29 SG SG11201901716TA patent/SG11201901716TA/en unknown
- 2017-08-29 KR KR1020197008941A patent/KR102427563B1/ko active Active
- 2017-08-29 JP JP2019507924A patent/JP2019532621A/ja active Pending
- 2017-08-29 WO PCT/EP2017/071674 patent/WO2018041838A1/en not_active Ceased
- 2017-08-29 CN CN202410956740.6A patent/CN119614520A/zh active Pending
- 2017-08-29 WO PCT/EP2017/071655 patent/WO2018041827A1/en not_active Ceased
- 2017-08-29 CN CN201780056486.2A patent/CN109862912B/zh active Active
- 2017-08-29 CN CN202410962886.1A patent/CN119592523A/zh active Pending
- 2017-08-29 CA CA3034517A patent/CA3034517A1/en active Pending
- 2017-08-29 US US16/329,125 patent/US12258417B2/en active Active
- 2017-08-29 IL IL303187A patent/IL303187A/en unknown
- 2017-08-29 SG SG11201901715UA patent/SG11201901715UA/en unknown
- 2017-08-29 EP EP23170482.6A patent/EP4273252A3/en active Pending
- 2017-08-29 EP EP17771343.5A patent/EP3503918B1/en active Active
- 2017-08-29 BR BR112019003866A patent/BR112019003866A2/pt unknown
- 2017-08-29 MY MYPI2019000750A patent/MY197324A/en unknown
- 2017-08-29 ES ES17771344T patent/ES2983916T3/es active Active
- 2017-08-29 EP EP17771344.3A patent/EP3503919B1/en active Active
- 2017-08-29 AU AU2017320776A patent/AU2017320776B2/en active Active
- 2017-08-29 MX MX2019002328A patent/MX2019002328A/es unknown
-
2019
- 2019-01-30 ZA ZA2019/00644A patent/ZA201900644B/en unknown
- 2019-02-26 CL CL2019000510A patent/CL2019000510A1/es unknown
- 2019-02-26 MX MX2023008779A patent/MX2023008779A/es unknown
- 2019-02-28 PH PH12019500436A patent/PH12019500436A1/en unknown
- 2019-03-14 CO CONC2019/0002371A patent/CO2019002371A2/es unknown
-
2022
- 2022-08-17 JP JP2022130173A patent/JP7525558B2/ja active Active
-
2024
- 2024-06-14 US US18/744,059 patent/US20250026851A1/en active Pending
- 2024-07-18 JP JP2024114614A patent/JP2024147722A/ja active Pending
-
2025
- 2025-01-09 AU AU2025200140A patent/AU2025200140A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534036A5 (enExample) | ||
| JP2024147722A5 (enExample) | ||
| Zhao et al. | Th17 cells in inflammatory bowel disease: cytokines, plasticity, and therapies | |
| Gallagher et al. | Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses | |
| Chang et al. | IL-17F: regulation, signaling and function in inflammation | |
| CN112105633A (zh) | 新型白介素2及其用途 | |
| Savan et al. | Cloning, characterization and expression analysis of interleukin‐10 from the common carp, Cyprinus carpio L. | |
| van der Bruggen et al. | Interleukin-5 signaling in human eosinophils involves JAK2 tyrosine kinase and Stat1 alpha | |
| Shekhar et al. | Interleukins profiling for biosensing applications: possibilities and the future of disease detection | |
| Nishimoto et al. | Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation | |
| JP2002524537A5 (enExample) | ||
| DiCarlo et al. | Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children | |
| Cameron et al. | Cytokines and chemokines-their receptors and their genes: an overview | |
| B Maschio-Signorini et al. | Melatonin regulates angiogenic and inflammatory proteins in MDA-MB-231 cell line and in co-culture with cancer-associated fibroblasts | |
| RU2015148920A (ru) | Расширенная адоптивная клеточная терапия | |
| RU2007129263A (ru) | Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение | |
| JP2013516194A5 (enExample) | ||
| Tsuboi et al. | Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma | |
| JPWO2021189059A5 (enExample) | ||
| Bauer | Interleukin-6 and its receptor during homeostasis, inflammation, and tumor growth | |
| Kashfi et al. | Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer | |
| Seelige et al. | Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection | |
| JP2018529339A5 (enExample) | ||
| Lee et al. | Interleukin‐4 inhibits the expression of tumour necrosis factors α and β, interleukins‐1 β and‐6 and interferon‐γ | |
| LAI et al. | Anti‐DNA autoantibodies stimulate the release of interleukin‐1 and interleukin‐6 from endothelial cells |